Christopher Pleyer, MD, discusses the next steps with the combination of ibrutinib and short-course fludarabine in previously untreated chronic lymphocytic leukemia.
Christopher Pleyer, MD
Advertisement
Articles by Christopher Pleyer, MD
Christopher Pleyer, MD, discusses the safety and effectiveness of ibrutinib plus short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
2
Retrospective Data Show Zanubrutinib May Less AFib Burden in Real-World CLL
3
Dato-DXd Hits Key Secondary Efficacy End Points in First-Line TNBC
4
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
5